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Red tides have been documented on the Gulf
Coast of Florida as early as 1530 (Taylor
1917). They occur nearly annually and often
persist for many months (Woodcock 1948).
The causative organism for these events,
Karenia brevis (formerly Gymnodinium breve
and Ptychodiscus brevis) produces a family of
neurotoxins, collectively called brevetoxins
(Martin and Chatterjee 1969; Steidinger and
Joyce 1973). These events are responsible for
ﬁsh, waterfowl, and marine mammal mortal-
ities (Davis 1948) as well as human intoxi-
cation (Lin et al. 1981). The accumulation
of brevetoxins in shellfish can lead to the
neurotoxic shellfish poisoning syndrome in
humans (McFarren et al. 1965), which,
before 1993, was believed to be restricted to
the southeastern United States. However, in
1993 neurotoxic shellfish poisonings and
brevetoxin contamination of shellfish were
reported in New Zealand (Mackenzie et al.
1996). The causative organism in the New
Zealand waters was reported to be K. brevis or
a closely related species (Satake et al. 1996).
Subsequently, three different genera of the
family Raphidophyceae (Chattonella marina,
Fibrocapsa japonica, Heterosigma akashiwo)
isolated from Japanese waters have been
reported to produce a neurotoxin similar to
brevetoxins (Kahn et al. 1995, 1996, 1997).
In 2002, brevetoxin was conﬁrmed to be pro-
duced by the raphidophytes C. marina and
Chattonella antiqua (Haque and Onoue 2002),
and samples from mid-Atlantic waters con-
taining Chattonella species have been reported
to contain brevetoxin (Bourdelais et al. 2002).
The broad distribution of raphidophytes
opens the concern of a widespread occurrence
of this family of toxins.
Brevetoxins are analyzed largely to assure
shellﬁsh safety and on an as-needed basis for
marine mammal and human intoxications. In
the Gulf of Mexico, substantial monitoring is
conducted for the causative organism, K. bre-
vis, to prevent the harvest of contaminated
shellfish beds. At present, toxin detection is
conducted by the mouse bioassay (Delaney
1985); however, several functional assays are
employed as potential alternatives to the
mouse bioassay (Dickey et al. 2002). In the
case of marine mammal and human intoxica-
tions, brevetoxin has been detected in isolated
cases by functional assays and liquid chro-
matography–mass spectrometry (LC-MS) in
tissues from bottlenose dolphins (Mase et al.
2000) and West Indian manatees (Landsberg
and Steidinger 1997) and in urine from
intoxicated humans (Poli et al. 2000).
A critical need exists for a simple and reli-
able detection method that can be used to
routinely monitor aquatic animals and humans
for brevetoxins. Fairey et al. (2001) described
the application of a blood collection card
method (Adam et al. 2000) to facilitate sam-
pling and processing of blood samples from
brevetoxin-exposed animals. The method of
Fairey et al. (2001) uses a microplate receptor-
binding assay (RBA) to screen samples for
brevetoxin-like activity and LC-MS to conﬁrm
the presence of brevetoxin. In this article, we
describe a brevetoxin radioimmunoassay (RIA)
that we developed using a format parallel to
the RBA, and compare the methods for detec-
tion of brevetoxin in the blood of exposed ani-
mals. We have determined that the RIA
provides greater sensitivity and allows detec-
tion of blood brevetoxin at nonsymptomatic
doses and for longer times postexposure.
Materials and Methods
Brevetoxin mouse exposure. For the short-term
study and the dose response, female ICR mice,
18–20 g, were obtained from Harlan Sprague
Dawley (Indianapolis, IN, USA). The mice
were kept for 24 hr with food and water given
ad libitum. The mice were injected intraperi-
toneally (IP) with the brevetoxin congener
PbTx-3 in phosphate-buffered saline (PBS) at
180 µg/kg body weight (bw) for the 24-hr
study and at 10–300 µg/kg bw for the dose
response. The control mice were injected with
1.66% methanol in PBS. The behavior and
symptomatology of the mice were recorded for
both studies. The blood was collected after 0.5,
1, 2, 4, and 24 hr for the short-term study, and
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We developed a radioimmunoassay (RIA) using a sheep anti-brevetoxin antiserum to evaluate detec-
tion of brevetoxin on blood collection cards from mice treated with the brevetoxin congener PbTx-3.
The RIA has high afﬁnity for PbTx-3 [half-maximal effective concentration (EC50) ± SE = 1.2 ±
0.2 nM; n = 10] and recognizes both type 1 and type 2 brevetoxins, but not ciguatoxin. Direct com-
parison of the RIA with a radiolabeled [3H]-PbTx-3 receptor-binding assay (RBA) revealed excellent
sensitivity, congener selectivity, and minimal interference from blood matrix. We first analyzed
blood samples from an acute time course exposure, using a maximal nonlethal dose [180 µg/kg body
weight (bw)] for 0.5, 1, 2, 4, and 24 hr. Mean blood brevetoxin levels were 36 nM at 30 min and
stayed above 20 nM during the 1–4 hr time points. We next analyzed blood brevetoxin levels after
longer exposure (0.5, 1, 2, 3, 4, or 7 days). Mean blood brevetoxin levels were 26.0 nM at 0.5 days,
decreased to 8.2 nM at 1.0 day, and maintained a signiﬁcant level (p < 0.05) of 1.3 nM at day 2. We
next determined the lowest measurable dose using increasing concentrations of PbTx-3 (10–300
µg/kg bw). Analysis of the blood samples at 60 min revealed a linear relationship between adminis-
tered and internal doses (r2 = 0.993). All doses of brevetoxin administered were detectable at 1 hr,
with signiﬁcant levels found for the lowest administered dose of 10 µg/kg bw—a dose that was 10-
fold lower than the lowest observable effect level. This RIA provides an optimal ﬁrst-tier detection of
brevetoxin from blood collection cards and, used in combination with the RBA and liquid chro-
matography–mass spectrometry, should provide a complete panel of methods to biomonitor breve-
toxin exposure. Key words: blood, brevetoxin, radioimmunoassay. Environ Health Perspect
111:1595–1600 (2003). doi:10.1289/ehp.6166 available via http://dx.doi.org/ [Online 2 July 2003]
Research | Articleafter 1 hr for the dose response. At each time
point or PbTx-3 concentration, four mice were
anesthetized with 2.0 mg ketamine (Parke-
Davis, Morris Plains, NJ, USA) and 0.2 mg
Prom ACE (Aveco, Fort Dodge, IA, USA) in a
volume of 100 µL PBS. The mice were then
exsanguinated via cardiac puncture to the left
ventricle with a lithium heparinized 1-cc
syringe. We applied 100 µL of blood to each
spot on the blood spot collection card. For the
long-term study we used female CD-1 mice
(Charles River Laboratories, Raleigh, NC,
USA); the procedure used for treatment of
these animals was previously described by
Gordon et al. (2001). 
Blood collection. Blood (100 µL) was
applied to each circle on the grade-903 ﬁlter-
paper blood collection card (Schleicher &
Schuell, Keene, NH, USA). The cards were
then allowed to dry overnight in a cool, dark
environment. Once the cards were dry, they
were separated by 6-in. × 6-in. weighing paper
(VWR Scientific Products, Suwanee, GA,
USA) and transferred to airtight plastic bags
(VWR Scientiﬁc Products) containing desic-
cant packages (Multisorb Technologies Inc.,
Buffalo, NY, USA) and humidity cards
(Multisorb Technologies Inc.). The cards were
stored at –20°C until use.
Brevetoxin extraction from blood collection
cards. The dried blood spots were prepared and
processed the same way for both the RIA and
the RBA. The entire 100 µL dried blood spot
was cut from the cellulose blood collection card
and extracted overnight in 2 mL methanol in a
12 × 75 mm test tube. The spots were removed
from the tubes, and the methanol extracts were
brought to dryness with nitrogen using a
Turbovap LV evaporator (Zymark, Hopkinton,
MA, USA) and then stored at –20°C until use.
The blood spot extracts were resuspended in
the original spot volume of 100 µL containing
90 µL RIA or RBA assay buffer and 10 µL
methanol. Whole mouse blood (Harlan
Bioproducts, Indianapolis, IN, USA) was used
for blood spots spiked with 20 nM PbTx-3
(Calbiochem, San Diego, CA, USA), which
were used as a quality check.
Immunizations. Groups of four sheep
were immunized with PbTx-2 conjugated to
ovalbumin and fetuin. For primary immuniza-
tions, immunogens were prepared as water-in-
oil suspensions by injecting the conjugate,
dissolved in PBS (1 mg protein in 1 mL), into
2 mL Freund’s complete adjuvant, followed
by vortex mixing. Immunogens for secondary
and subsequent immunizations (up to eight
boosts) were administered as emulsions in
Freund’s incomplete adjuvant.
The immunogen emulsion (0.5 mL) was
administered intramuscularly into the semi-
tendinosus muscle, 0.25 mL per hind leg, via
a 20-gauge needle. Test bleeds (10 mL
Vacutainer, no. 366430; Becton Dickinson,
Franklin Lakes, NJ, USA) were taken from
the jugular vein 14 days after the third and
subsequent immunizations, and antibody
titers were determined by enzyme-linked
immunosorbent assay (ELISA). Larger vol-
umes of blood for antiserum production were
obtained by venipuncture and collected into
blood bags (Blood bag no. 4R0001; Baxter,
Deerﬁeld, IL, USA) under negative pressure,
from sheep identiﬁed as having high titers. A
series of three injections at 4-week intervals
was followed by a rest period, with subse-
quent boosts at no less than 4-week intervals.
Antiserum from animal 7098, immunized
with PbTx-2–fetuin conjugate, was chosen
for use in the development of both the ELISA
and the RIA because of its high antibody titer
and competitive binding of both free PbTx-2
and the PbTx–protein conjugates. All animal
manipulations were performed under the
authority of the AgResearch Ruakura Animal
Ethics Committee.
Radioimmunoassay. RIAs were run in 12 ×
75 borosilicate glass tubes in PBS containing
137 mM NaCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4, and 2.7 mM KCl (all from Sigma
Chemical Company, St. Louis, MO, USA),
and 0.01% Emulphor-EL 620 (GAF, New
York, NY, USA. The assay tubes consisted of
PbTx-3 standard or blood spot extract (50 µL),
anti-PbTx antiserum (1:4,000), and [3H]-
PbTx-3 (0.4 nM) in PBS (ﬁnal assay volume of
500 µL). The six PbTx-3 standards ranged
from 0.01 nM to 100 nM. The PbTx-3 stan-
dards and blood spot extracts were allowed to
preincubate in buffer at room temperature
with the anti-PbTx-3 antibody for 1 hr before
the [3H]-PbTx-3 tracer was added. The tubes
were placed on a shaker (Titramax 100;
Heidolph Instruments, Cinnaminson, NJ,
USA) and incubated for another hour after the
addition of the radioactive toxin. Sac-Cel
(Alpco Diagnostics, Windham, NH, USA) was
then added to the assay tubes to allow for the
separation of bound and unbound brevetoxin.
The Sac-Cel was ﬁltered onto 25-mm GF/C
glass fiber filters (Whatman, Newton, MA,
USA). Each assay tube was rinsed three times
with 2 mL PBS. The filters were placed in
3.5 mL Scinti-verse (Fisher, Suwanee, GA,
USA), and the radioactivity was counted on a
1211 RackBeta liquid scintillation counter
(Wallace-Perkin Elmer, Wellesley, MA, USA).
Receptor-binding assay. RBAs were run
using the same per-tube assay volume and the
same six RIA PbTx-3 standards. The RBAs
were carried out in 12 × 75 mm tubes in
binding buffer consisting of 50 mM HEPES
(pH 7.4), 130 mM choline chloride, 5.5 mM
glucose, 0.8 mM magnesium sulfate, 5.4 mM
potassium chloride, 1 mg/mL bovine serum
albumin, and 0.01% Emulphor EL 620. Each
assay tube contained PbTx-3 standards or
blood spot extract (50 µL), [3H]-PbTx-3
(1 nM), and rat brain membrane preparation
(80–100 µg protein/mL) in binding buffer
(500 µL total volume). Tubes were incubated
for 1 hr at 4°C. The membranes were ﬁltered
and counted as described above for RIA.
Toxin congener recognition. The RIA and
the RBA were used to evaluate toxin con-
gener recognition using PbTx-1, PbTx-2,
PbTx-6, and PbTx-9 (Molecular Probes,
Inc., Eugene, OR, USA). Caribbean cigua-
toxin (CCTX-1) was provided by R. Dickey
(Food and Drug Administration, Gulf Coast
Seafood Laboratory, Dauphin Island, AL).
Data analysis. All concentrations and half-
maximal effective concentration (EC50) values
were determined using Prism Graph Pad 3.0
(GraphPad Software, Inc., San Diego, CA,
USA). Where appropriate, signiﬁcance values
were determined by analysis of variance using
JMP statistical software (SAS Institute, Cary,
NC, USA).
Results
Using a sheep antibody directed against a
PbTx-2–fetuin conjugate, we have developed
an immunoassay to analyze blood cards for
brevetoxin. In order to facilitate comparison
with the RBA, we developed the RIA to be a
competitive binding assay, run in solution with
separation by ﬁltration. Comparison of stan-
dard curves for PbTx-3 revealed high sensitiv-
ity for both assays (Figure 1). However, there
was a significant difference between the RIA
and RBA in the calculated EC50 (p < 0.001).
The RIA produces a standard curve for PbTx-3
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Figure 1. Comparison of standard curves for the RIA
(A) and the RBA (B). The two standard curves were
derived as described in “Materials and Methods.“
The RIA (A; EC50 = 1.2 nM) displays a higher sensitiv-
ity than does the RBA (B; EC50 = 4.0 nM). Data shown
are individual standard curves with EC50 that have
been repeated multiple times. Error bars indicate SE.
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Bwith a limit of detection (± SE) of 0.31 ± 0.06
nM and EC50 = 1.2 ± 0.2 nM (n = 10). Using
the RBA, the calculated limit of detection for
PbTx-3 was 1.01 ± 0.38 nM and EC50 = 4.0 ±
1.5 nM (n = 7), which is 3-fold higher than
that for the RIA.
We next examined the matrix effect of the
blood cards on the RIA and RBA. Dried
blood spots collected from control animals
were extracted and added to assay tubes con-
taining the PbTx-3 standard curve. The pres-
ence of matrix caused a minor reduction in
total binding in the RIA (11%) and RBA
(15%), with no apparent effect on relative
afﬁnity (Figure 2).
We next examined toxin congener recogni-
tion between the two assays. The afﬁnity of the
antibody for each toxin was determined by
reporting the ratio of PbTx-3 equivalents
detected by RBA to those detected by RIA.
Three brevetoxin congeners (PbTx-2, PbTx-3,
and PbTx-9) showed very comparable afﬁnities
for each assay method. However, the RIA had
a higher afﬁnity for PbTx-6 and a lower afﬁn-
ity for PbTx-1 (Table 1). Overall, this compar-
ison of the RBA with the RIA yields a rank
order of affinity of PbTx-6 > 3 = 2 = 9 > 1.
Unlike the RBA, the RIA did not recognize the
CCTX-1 (data not shown). 
We next analyzed a sample set from an
acute time-course exposure that was identical
to the sample set previously analyzed by Fairey
et al. (2001) using the microplate receptor-
binding assay and LC-MS. Mice were treated
IP with a high, sublethal dose of PbTx-3 (180
µg/kg bw), and blood was collected at 0.5, 1,
2, 4, and 24 hr. Blood brevetoxin levels were
at mean levels of 36 M at 30 min and main-
tained levels near 25 nM during the 1-, 2-,
and 4-hr time points (Figure 3). At 24 hr,
brevetoxin was still detectable (3.3 nM) at lev-
els significantly different from those in non-
treated animals (p = 0.002).
Given that we could still detect brevetoxin
in blood a full day after exposure, we analyzed
blood brevetoxin exposure after longer dura-
tions. Using a sample set collected 2.5 years
earlier for experiments described by Gordon
et al. (2001), we extracted the blood and con-
ducted brevetoxin analysis by RIA. Mice
(CD-1 rather than ICR strain) were treated
with 180 µg/kg bw PbTx-3, and groups of
four mice were bled at 0.5, 1, 2, 3, 4, or 7
days. The mean blood brevetoxin value at 0.5
days was 26.0 nM and then decreased to
8.2 nM at 1 day and maintained levels
around 1.3 nM until day 3 (Figure 4). The
brevetoxin was detected in animals 3, 4, and 7
days after treatment; however, these levels did
not significantly (p > 0.05) differ from the
vehicle-treated animals.
As a final experiment, we examined the
dose response for brevetoxin to determine the
lowest dose at which we could detect blood
brevetoxin levels using blood collection cards
and RIA detection. ICR mice were treated
with increasing concentrations of PbTx-3
(10–300 µg/kg bw), and their symptoms were
recorded by observation over the course of 60
min (Table 2). Blood was collected at 60 min
and applied to blood collection cards. The
lowest observable effect level was 100 µg/kg
bw PbTx-3, with the symptoms of hind limb
paralysis, chewing, and seizures observed.
Three mice in the 200 µg/kg bw group and
all four mice in the 300 µg/kg group died
within the 60-min trial. All doses of breve-
toxin administered were detectable at 1 hr,
with significant levels found for the lowest
administered dose of 10 µg/kg bw, a dose that
was 10-fold lower than the lowest observable
effect dose of 100 µg/kg bw (Figure 5).
Analysis of the blood samples by RIA revealed
a linear relationship (r2 = 0.993) between
administered and internal dose (Figure 6).
Discussion
In this article, we have compared an antibody-
based assay with an RBA for the detection of
brevetoxins from blood collection cards of lab-
oratory mice exposed to brevetoxin. The RIA
provides more sensitive detection with mini-
mal interference from residual matrix after
extraction of blood from the cards. The RIA
allowed detection of brevetoxin at doses 10
times lower than the lowest observable effect
level and at times up to 2 days after exposure.
Toxin detection methods are classiﬁed as
analyses or assays, based on whether a sample
value is measured with or without separation of
active components. Functional, nonanimal
assays for brevetoxins include RBAs, immuno-
assays (including both solid-phase nonradio-
metric ELISA and liquid-phase radiometric
RIA), and cell-based assays (cytotoxicity and
reporter gene; Van Dolah and Ramsdell 2001).
A primary difference in the assays is the initial
level of recognition at the receptor target
Article | Comparison of receptor and immunoassays for brevetoxin
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Table 1. Relative afﬁnities of brevetoxin congeners
for the RBA and RIA.
Congener RBA:RIA
PbTx-1 26.4
PbTx-2 1.2
PbTx-3 1.1
PbTx-9 0.8
PbTx-6 0.4
Five brevetoxin congeners of approximate microgram
weight suspended in methanol were tested in the RBA and
RIA and calibrated to PbTx-3 equivalents. The data are
reported as ratio of the PbTx-3 equivalents as determined
by the RBA versus RIA. The data are provided as ratios
rather than traditional ED50 values because two of the con-
geners were of too small a mass to be dried and weighed.
Figure 2. Comparison of brevetoxin standard
curves in the absence and presence of dried blood
matrix. The RIA (A) and the RBA (B) yield a small
reduction in total [3H]-PbTx-3 binding, 11% and
15%, respectively. Nonetheless, there was no sig-
niﬁcant difference in EC50 between the curves with
matrix as opposed to those without matrix. Error
bars indicate SE.
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Figure 3. Blood brevetoxin levels after acute breve-
toxin exposure. Mice were treated with 180 µg/kg
bw PbTx-3 IP and blood was collected from four
mice at each time point (0.5, 1, 2, 4, and 24 hr). The
blood PbTx-3 level remained near 25 nM for the
first 4 hr and declined to 3.3 nM by 24 hr. Results
shown are mean ± SE for four animals at each time
point from a single experiment.
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Figure 4. Blood brevetoxin levels after long-term
brevetoxin exposure. Mice were treated with
180 µg/kg bw PbTx-3 IP, and blood was collected
from four mice at each time point (0.5, 1, 2, 3, 4, and
7 days). A significant level of brevetoxin, 1.3 nM,
could be detected up to 2 days after exposure.
Days 3, 4, and 7 all showed detectable brevetoxin,
but not in concentrations significantly different
than that of the control. Results shown are for four
animals at each time point from a single experi-
ment. Results shown are mean ± SE.
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Control 0.5 1 2 3 4 7(RBAs and cell-based assays) or by an antibody
(RIA and ELISA). In our previous study
(Fairey et al. 2001), we examined brevetoxin in
mouse blood extract by RBA and by analysis
by LC-MS. In an effort to maintain similar
formats for comparison, we developed an RIA
using the same radioligand and separation
method as we used in the RBA. The antibody
used for this work had previously been used in
an ELISA format (Garthwaite et al. 2001)
RIAs have previously been described for
brevetoxins to include two types, based on the
brevetoxin conjugate linkage used for antibody
production. Baden et al. (1984) prepared a
PbTx-3–succinate derivative coupled by amine
bond to bovine albumin by carbodiimide con-
densation and produced antibodies in goats,
whereas Levine and Shimizu (1992) prepared a
PbTx-2 conjugate coupled via an amide bond
to bovine albumin by sodium borohydride
reduction and produced antibodies in rabbits.
Both conjugation methods link albumin to the
C-42 on the K-ring of brevetoxin; however,
the chemical linkage differs both in composi-
tion and length in the two preparations. Poli et
al. (1995) compared the two antibody prepara-
tions and found EC50 values about 10 times
lower for the rabbit antibody directed against
the PbTx-2 conjugate (0.2 vs. 3.0 ng/mL). To
produce the antiserum used in our study, we
followed Levine and Shimizu’s (1992) method
of conjugating PbTx-2 to fetuin. The EC50 of
1.5 nM for this antibody falls within the range
of the previously reported RIAs.
Antisera produced using both conjugation
procedures detect the type 2 brevetoxins
(PbTx-1, PbTx-7, and PbTx-10) poorly rela-
tive to the type 1 brevetoxins (PbTx-2,
PbTx-3, PbTx-5, PbTx-6, and PbTx-8). We
found that the difference between type 2 and
type 1 brevetoxins is approximately 4-fold for
our antiserum. The differences range from
> 500-fold reported by Levine and Shimizu
(1992), to 100-fold reported by Poli and
Hewetson (1992), to 4.5-fold reported by
Baden et al. (1984). This indicates that the
sheep antibody described here shows a lower
degree of selectivity for the type 2 backbone
of brevetoxins and may be more applicable
for detection of toxins containing both back-
bone structures.
In the ﬁrst phase of our investigation, we
compared this RIA with the RBA using an
identical format. We found that the RIA had
an EC50 that was three times lower than the
RBA (1.2 nM vs. 4.0 nM). In an earlier
comparison of the RIA (goat antibody) and
the RBA, Baden et al. (1988) found that the
RIA was less sensitive than the RBA (EC50
of 20 vs. 12 nM). The differences may be
due to the format in which the assays were
conducted. When comparing the selectivity
for brevetoxin congeners between the two
assay methods, we found that the differences
between the methods for brevetoxin type 1
and type 2 backbones differ by approximately
26-fold, a value consistent with that reported
by Baden et al. (1988). Thus, although the
RIA detects both brevetoxin backbone struc-
tures, in terms of pharmacologic activity the
RIA substantially underestimates the type 2
brevetoxins. This critical difference underlies
a major difference in methods based on recep-
tors versus antibodies: receptor-based assays
are more closely correlated to animal-based
assays and toxicity than are assays based on
antibodies (Van Dolah and Ramsdell 2001).
Biologic monitoring for brevetoxins
requires measurement of toxin levels in acces-
sible tissues (e.g., blood, hair, urine, and cir-
culating or accessible cells) in order to assess
exposure. Toxicokinetic studies have been
conducted using radiolabeled brevetoxin by
several routes of administration [oral (Cattet
and Geraci 1993), intravenous (Poli et al.
1990), inhalation (Benson et al. 1999)]; how-
ever, only Poli et al. (2000) have quantified
brevetoxins in clinical samples after exposure.
Poli et al. (2000) examined urine and serum
samples from two individuals with neurotoxic
shellfish poisoning and found that the urine
analysis was positive, but brevetoxins were not
detectable in serum because of more rapid
clearance from serum and matrix interference
of serum. We have applied the blood collec-
tion card method for marine toxin analysis to
allow monitoring of brevetoxins in whole
blood with minimal matrix interference. The
extraction of dried blood from cellulose cards
with methanol provides an excellent separa-
tion because the methanol ﬁxes much of the
blood matrix to cellulose while providing
high recovery of the toxin. The extracts from
control blood have caused a small inhibitory
effect in the RBA (Fairey et al. 2001). We
have examined this matrix effect by construct-
ing brevetoxin standard curves in the absence
and presence of extracted blood matrix for
both the RBA and the RIA. In the RIA we
observed an 11% decrease in total binding
with the extracted blood matrix and no signif-
icant change in EC50 for brevetoxin. These
data indicate that blood may indeed provide
the optimal collection ﬂuid for biomonitoring
of brevetoxin exposure. Furthermore, blood
collection cards provide a simple and effective
method of sample collection and storage for
both the clinic and the ﬁeld.
Our first exposure experiment for the
brevetoxin RIA of blood cards was a time-
course study designed to reproduce the data
obtained by the RBA and LC-MS by Fairey et
al. (2001). Using the RIA, we were able to
detect brevetoxin in blood at all time points
(0.5, 1, 2, 4, and 24 hr) and for each of the
four animals per treatment group. By contrast,
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Table 2. Observable symptoms in mice after brevetoxin exposure.
Dose Difﬁculty Hindlimb Rolling Forelimb Hindlimb
(µg/kg bw) breathing paralysis Chewing on back extension extension Seizing
0 (control) NO NO NO NO NO NO NO
10 NO NO NO NO NO NO NO
25 NO NO NO NO NO NO NO
50 NO NO NO NO NO NO NO
100  NO 30 min 25 min NO NO 15 min 15 min
200  NO 5 min NO 15 min NO NO 10 min
300  10 min 5 min 15 min 10 min 15 min NO 5 min
NO, not observed more than 60 min after toxin administration. Mice were treated IP with increasing doses of brevetoxin,
and observable symptoms were recorded at the earliest onset of occurrence. The observation period was time of injection
to 60 min postinjection, at which time the animals were sacriﬁced for blood collection.
Figure 5. Blood brevetoxin levels after low-dose
brevetoxin exposure. Mice were treated with
PbTx-3 IP, and blood was collected from all four
mice at each dose [0 (control) and 10, 25, 50, 100,
200, 300 µg/kg bw] after 1 hr exposure. The plot of
average blood PbTx-3 concentration demonstrates
that PbTx-3 can be detected at doses 10 times
lower than symptomatic levels (100 µg/kg bw).
Results shown are mean ± SE.
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Figure 6. Blood brevetoxin levels after low-dose
brevetoxin exposure. The plot of the internal dose
versus external dose yields an r2 value of 0.993.
The PbTx-3 concentrations were calculated by
subtracting the control value (0 dose) from the
mean for duplicate blood spots from one animal.
The results indicate mean ± SE for four animals at
each concentration from a single experiment.
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05 0 100 150 200 250 300 350in our earlier study using a microplate receptor
assay (Fairey et al. 2001), although brevetoxin
activity was detectable in all experimental
groups, only in the 4.0-hr treatment was
brevetoxin detected in all four animals. In
this earlier study, the mean brevetoxin level
(± SE) measured by the RBA at 4 hr treat-
ment was 25 ± 7 nM, which compares well
with that found in the present study mea-
sured by RIA, a mean value of 27 ± 7 nM at
4 hr treatment. The similar measurements,
yet less consistent brevetoxin detection of the
RBA in our earlier report, may be due, at
least in part, to the lower reaction volume of
the microplate format.
We next decided to examine RIA detection
of blood cards at longer periods of brevetoxin
exposure. In an earlier study (Gordon et al.
2001), we reported a delayed thermoregulatory
response to brevetoxin in mice. This delayed
response was persistent hyperthermia, which
was distinct from the rapid onset hypothermia
commonly reported in response to polyether
toxins. At that time, we collected blood from
four animals each at the 0.5-, 1-, 2-, 3-, 4-, and
7-day time points. The samples were applied to
blood collection cards that were stored 32
months before measurement by RIA. The level
of brevetoxins detected by RIA were elevated
for 12 hr, were reduced by one-third by 24 hr,
maintained a signiﬁcant level above control by
day 2, and were detectable but not at signiﬁ-
cant levels for days 3, 4, and 7. These ﬁndings
are consistent with the toxicokinetic study of
Cattet and Geraci (1993), who found that
radiolabeled [3H]-PbTx-3 was detectable up to
8 days after oral exposure. Taken together,
these ﬁndings indicate that nonlethal exposures
to brevetoxin may be measurable up to 2 days
after exposure using RIA measurement by
blood collection cards.
The final exposure we conducted was a
dose dependency. The doses chosen ranged
from 10 to 300 µg/kg bw PbTx-3, which is
5.5–167% of the maximally tolerable dose
(180 µg/kg bw) used for our previous studies
(Fairey et al. 2001; Gordon et al. 2001). We
chose blood measurements for 60 min based
on our findings of a plateau value of 25–30
nM for time points between 1 and 12 hr after
exposure. Based on observable symptoms, we
were able to establish 100 µg/kg bw as the
lowest observable effect level. An acute
decrease in core body temperature was observ-
able only at 200 µg/kg bw and 300 µg/kg bw.
Measurement of blood brevetoxin by RIA
revealed a linear relationship between admin-
istered and internal dose for the 1-hr expo-
sure. Brevetoxin was measurable by RIA at all
tested doses with significant amounts at the
lowest dose of 10 µg/kg bw. These results
indicate that brevetoxin can be measured
from blood collection cards at doses 10 times
lower than the dose causing the lowest
observable symptoms in mice. Taken together
with the ﬁnding that blood brevetoxin levels
are comparable between 1 and 12 hr, this
indicates that biomonitoring of brevetoxin by
RIA of blood cards may be feasible at non-
symptomatic exposure levels.
A relevant question exists as to how well the
IP dosing of PbTx-3 in mice models the expo-
sure of humans and aquatic species to toxin in
algae, toxin released from algae into the water
or aerosol, and toxin accumulated in the food
web? Preliminary studies in our laboratory with
mice given PbTx-3 orally and ﬁnﬁsh exposed to
K. brevis in aquaria (unpublished data) gave
results similar to those reported here. Another
potential concern lies in the detection of
brevetoxin metabolites. K. brevis is reported to
produce brevetoxin congeners 2, 1, and 3 in
the ratio of 20:4:1 (Roszell et al. 1989). The
predominantly occurring brevetoxin in algae,
PbTx-2, is rapidly reduced to the more stable
PbTx-3. Following the neurotoxic shellﬁsh poi-
soning in New Zealand (Mackenzie et al. 1996;
Satake et al. 1996), four brevetoxin metabolites
were described, including a taurine conjugate,
an S-cysteine conjugate, and fatty acid esters
(Ishida et al. 1996; Morohashi et al. 1995,
1999; Murata et al. 1998). Subsequently, Poli
et al. (2000) reported brevetoxin activity consis-
tent with metabolites from shellfish from
Florida coastal waters, and Plakas et al. (2002)
identiﬁed these as cysteine conjugates. In addi-
tion, Poli et al. (2000) puriﬁed the two metabo-
lites and compared their activity by RIA and
RBA. The metabolites had activity comparable
with PbTx-3 by RIA; however, they had a third
less activity by RBA. Thus, RIA is likely to
detect the major brevetoxin conjugates found
both in algae and shellﬁsh; however, receptor-
based assays are necessary for precise toxicity
measurement.
In summary, we have found that the RIA is
more sensitive and has less matrix effect than
does the RBA when detecting PbTx-3 in
exposed mice using blood collection cards.
Nevertheless, the two assays complement one
another well when analyzing different PbTx
congeners. The RIA provides detection in
blood at brevetoxin exposures well below
symptomatic levels and allows detection up to
2 days after exposure. Taken together, these
results support the merits of tier-based testing
for brevetoxins: antibody methods provide a
good screening method, whereas receptor-
based methods provide a good toxicity mea-
surement, and LC-MS provides absolute
conﬁrmation of toxin congeners.
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